Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130746 | 0.82 | HTR2C (0.40) | HTR2CTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4972049 | 0.82 | HTR2C (0.40) | HTR2CTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL26419632 | 0.80 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3CNR2HTR2C | |
| SCHEMBL11592473 | 0.78 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3CNR2HTR2C | |
| SCHEMBL30998353 | 0.78 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3CNR2HTR2C | |
| SCHEMBL11592475 | 0.78 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3CNR2HTR2C | |
| SCHEMBL11592479 | 0.78 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3CNR2HTR2C | |
| SCHEMBL26419677 | 0.77 | TAS1R3 (0.39) | SLC6A2SLC6A4SLC6A3TAS1R3TAS1R1 | |
| SCHEMBL19497432 | 0.76 | CNR2 (0.41) | SLC6A2SLC6A4SLC6A3CNR2HTR2C | |
| SCHEMBL12705519 | 0.75 | CNR2 (0.37) | SLC6A2SLC6A4SLC6A3CNR2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130004-A1 | RELEASE LAYER COMPOSITION FOR TRANSFER OF COMPONENTS | TERECIRCUITS CORPORATION | 2023-04-27 | — | — | US | disclosed |
| EP-1924565-B1 | DIAMINOPYRIMIDINES AS P2X3 AND P3X2/3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-09-14 | — | — | EP | disclosed |
| US-7776872-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1924565-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P3X2/3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025900-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P3X2/3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049610-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049610-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | P2RX3, P2RX6, P2RX2 | SLC6A2 1467/4885SLC6A4 859/4885SLC6A3 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.